Source comparison
BPC-157 on Empty Stomach Safety: Quick Comparison
Subcutaneous injection 85–95% (relative to IV) 70–80% (delayed Tmax) 20–30 min before meals Excellent. No direct gastric contact Oral capsule 10–15% (high first-pass loss) 4–8% (protease degradation) 30+ min before meals or 2+ hrs after Well-tolerated. Cytopro
This comparison does not assign a generated winner or score.
- Subcutaneous injection
- 85–95% (relative to IV)
- 70–80% (delayed Tmax)
- 20–30 min before meals
- Excellent. No direct gastric contact
- Oral capsule
- 10–15% (high first-pass loss)
- 4–8% (protease degradation)
- 30+ min before meals or 2+ hrs after
- Well-tolerated. Cytoprotective effect documented
- Intramuscular injection
- 80–90% (relative to IV)
- 65–75% (delayed Tmax)
- Excellent. No gastric interaction
- Sublingual (compounded)
- 40–60% (bypasses first-pass)
- 20–35% (salivary dilution + swallowing)
- Hold under tongue 90+ sec, fasted
- Generally well-tolerated if mucosal contact minimised